AFMJF (AFMJF) Stock Price & Analysis
AFMJF (AFMJF) fell 3.47% to USD 0.98 as of June 9, 2026 at 23:35 UTC, according to Nexqual real-time market data.
AFMJF last closed at USD 1.01; the session ranged USD 0.95–0.98 on volume of 147,545 shares. Market capitalization is $1.25B, with a 52-week range of USD 0.57–1.2 (PNK). Source: Nexqual, June 9, 2026 at 23:35 UTC.
Key Statistics (as of June 9, 2026 at 23:35 UTC)
| Price | USD 0.98 |
|---|---|
| Change | ▼ 3.47% (down) |
| Previous Close | USD 1.01 |
| Open | USD 0.96 |
| Day Range | USD 0.95 – 0.98 |
| 52-Week Range | USD 0.57 – 1.2 |
| Volume | 147,545 shares |
| Market Cap | $1.25B |
| Exchange | PNK |
Technical Analysis (AFMJF)
Nexqual's technical model rates AFMJF "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.57 (neutral) |
| vs SMA50 | Below (USD 0.98) |
| MACD | 0 (positive) |
Analyst Ratings (AFMJF)
Wall Street analysts rate AFMJF "None", per Nexqual as of June 9, 2026 at 23:35 UTC.
| Consensus Rating | None |
|---|
Earnings (AFMJF)
| Next Earnings Date | 2026-07-29 |
|---|---|
| Revenue Estimate | $236.35M |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Financials & Fundamentals (AFMJF)
| Total Revenue | $740.47M |
|---|---|
| Revenue Growth (YoY) | +99.30% |
| Gross Margin | +54.82% |
| Operating Margin | +58.79% |
| Profit Margin | +25.49% |
| ROE | +48.17% |
| Debt / Equity | 8.19 |
| Current Ratio | 2.29 |
| Total Cash | $183.11M |
| Total Debt | $43.11M |
| Free Cash Flow | $261.62M |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Financial Health Score (AFMJF)
Nexqual rates AFMJF's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:35 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $183M cash vs $43M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $292M |
| Efficiency | Strong — ROE 48%, ROA 34.8% |
Ownership (AFMJF)
| Insider Ownership | +57.08% |
|---|---|
| Institutional Ownership | +6.37% |
| Shares Outstanding | 1.28B |
| Float | 551.20M |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Leadership (AFMJF)
AFMJF is led by Eoin O'Driscoll (age 42), Chief Executive Officer, per Nexqual as of June 9, 2026 at 23:35 UTC.
| Chief Executive Officer | Eoin O'Driscoll (age 42) |
|---|---|
| Non Executive Director & Corporate Secretary | Zain Madarun |
| Chief Financial Officer | JP Van Staden (age 52) |
| Managing Director of ABM | Jac Van Heerden |
Major Backers & Investors (AFMJF)
Notable institutional backers of AFMJF include Aegis Funds-Aegis Value Fund, T. Rowe Price, -Price (T.Rowe) International Small-Cap Equity Trust, according to Nexqual as of June 9, 2026 at 23:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Aegis Funds-Aegis Value Fund | 1.8% |
| T. Rowe Price | 1.34% |
| -Price (T.Rowe) International Small-Cap Equity Trust | 0.31% |
| Nationwide Mutual Funds-Nationwide International Small Cap Fund | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.4% |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MLXEF | Metals X, Ltd. | USD 1.16 | ▲ 5.65% |
| PAIOF | PAION AG | USD 0.01 | ▲ 0% |
| AGYTF | ALLERGY THERAPEUTICS | USD 0.13 | ▲ 0% |
| ABBRF | AbraSilver Resource Corp | USD 10.07 | ▼ 3.73% |
| GLATF | Global Atomic Corp. | USD 0.46 | ▼ 4.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:35 UTC. This page is informational and not investment advice.